AzTrials
AzTrials

Antisocial BehaviorNCT03035877

Multisystemic Therapy-Emerging Adults (MST-EA) for Substance Abuse

A study testing Multisystemic Therapy-Emerging Adults and Enhanced Treatment as Usual in people with Antisocial Behavior, run by Chestnut Health Systems at 4 sites in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This study's purpose is to examine the effectiveness of a promising intervention for emerging adults (EAs) with alcohol and other drug (AOD) abuse and justice involvement in achieving the ultimate outcome of reduced criminal activity. Read more about this study

Who is it for?
Ages 16 to 26 years
Conditions the study is for
Antisocial Behavior
What is being tested?
Multisystemic Therapy-Emerging Adults and Enhanced Treatment as Usual
Could I receive a placebo?
No, everyone receives an active treatment
How many people
183 participants
Where
4 sitesUnited States
Study dates
28 Aug 2017to 13 Apr 2023
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 16 to 26 years
  • All sexes
  • No healthy volunteers
  • Child, Adult

Who may be able to join

  • Age 16 to 26 years
  • Recent arrest or release from jail/prison/detention (within the past 18 months but excluding arrest for parole/probation violations)
  • Presence of alcohol or drug (AOD) abuse disorder and recent AOD use (within the past 90 days)
  • Able to reside in a stable community setting (not currently homeless, not currently in-patient; can include individuals ready for discharge to the community)

Who cannot join

  • Actively psychotic, suicidal, or homicidal
  • Pervasive Development Disorders (PDD) or mental retardation
  • Sex offending as the primary offense type

Trial locations and contacts

4 sites in 1 country.

United States4 sites
  • North American Family Institute

    Hamden, Connecticut, 06518

  • North American Family Institute

    Hartford, Connecticut, 06114

  • Youth Villages

    Johnson City, Tennessee, 37601

  • North American Family Institute

    New Haven, Connecticut, 06510

Other trials in United States

About this study

Official title: Treatment of Justice-Involved Emerging Adults With Substance Use Disorders

This study's purpose is to examine the effectiveness of a promising intervention for emerging adults (EAs) with alcohol and other drug (AOD) abuse and justice involvement in achieving the ultimate outcome of reduced criminal activity. The study will also examine that effect on intermediate outcomes as follows: 1) reduced AOD use; 2) greater gainful activity (increased educational success, employment and housing stability; decreased antisocial peer involvement and relationship conflict); 3) and greater improvement in self-regulation (self-efficacy, goal directedness and responsibility taking). The intervention to be tested is Multisystemic Therapy-Emerging Adults (MST-EA). MST-EA is an adaptation of MST, a well-established, effective intervention for antisocial behavior in adolescents.

Read the detailed description

Prevalence of alcohol and other drug (AOD) abuse and criminal activity is highest during emerging adulthood compared to any other developmental period, and causes extraordinary costs to society. Emerging Adults (EAs; ages 17-26) with AOD abuse have greater incarceration rates than EAs without AOD abuse, and AOD-abusing offenders have significantly more recidivism, severe offending, and incarceration than other offenders. Such serious behavior interferes with successful transition into adulthood in areas such as school completion, employment and housing. Thus, there is a strong public health need for effective treatment to reduce AOD abuse and justice involvement in EAs. Surprisingly, there are no interventions with established efficacy to reduce criminal activity among EAs, with or without AOD abuse. Among younger adolescents, the comprehensive causes of antisocial behavior are addressed by effective interventions (e.g., Multisystemic Therapy [MST]; Treatment Foster Care Oregon [TFCO]), and the present investigative team has developed and evaluated a well-defined age-tailored intervention for EAs with criminal behavior. The developed intervention is an adaptation of MST and integrates a skills coaching component from TFCO, both well-established effective juvenile justice interventions. Initial MST-EA research focused on justice-involved young adults who had mental health problems, a high-risk subpopulation of offenders, but AOD abuse quickly became a primary problem the MST-EA team treated. As a single-source intervention, MST-EA targets the EA correlates of criminal activity and AOD abuse, including gainful EA activities (positive relationships, school, work, and housing) and reduced AOD abuse-in part by targeting the proximal mechanism of poor self-regulation. In a successfully completed community-based open trial, the safety, feasibility, and preliminary efficacy of the intervention were established.

The proposed study will evaluate the effectiveness of MST-EA for reducing justice involvement and AOD abuse. EAs (n = 240) with AOD abuse and justice involvement (recent arrests or release from justice facilities) will be randomized to receive MST-EA or Enhanced Treatment as Usual (E-TAU). Assessments will be completed at months 0, 2, 4, 6, 8, 12, and 16, with confirmation of outcome data using official records. Aims will be to evaluate the effect over time of MST-EA for reducing AOD abuse and criminal activity, as well as to evaluate the effect of MST-EA on the key proximal target of treatment (self-regulation) and intermediate outcomes of treatment (gainful activities). A final aim of the study will be to investigate if the direct effect of treatment on criminal activity is mediated by its effect on self-regulation, AOD abuse, and gainful activities. In this specific age group, there is a complete absence of AOD abuse and recidivism reduction treatments with demonstrated effectiveness. The ultimate effect of the proposed research would be decreased AOD abuse and justice involvement in a high-risk population, as well as improved outcomes that have significant societal impact (e.g., reduced homelessness and unemployment).

Being tested
Multisystemic Therapy-Emerging Adults, Enhanced Treatment as Usual
Keywords
Antisocial Behavior, Alcohol Abuse, Drug Abuse, Young Adults
Medical subject headings
Antisocial Personality Disorder, Alcoholism, Substance-Related Disorders

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Multisystemic Therapy-Emerging AdultsBehavioural

    Also called MST-EA

    MST-EA is a home- and community-based treatment for emerging adults (ages 17-21) that aims to address antisocial behavior and problems caused by substance use disorders. The model also addresses co-occurring mental health problems when present. Therapists work directly with the young adult and his/her social network. This treatment also involves the use of coaches who help young people develop skills for young adulthood.

  • Enhanced Treatment as UsualBehavioural

    Also called E-TAU

    With Enhanced Treatment as Usual (E-TAU), emerging adults will get the treatments that they usually receive when they have a substance use disorder and have been in trouble with the law. In addition, they will receive travel vouchers for attending services, a card with an individualized list of contacts when in crisis, and facilitation with identifying need of services and accessing those services.

Study groups in NCT03035877
Study groupRoleWhat they receive
Multisystemic Therapy-Emerging AdultsExperimentalThis group will receive Multisystemic Therapy-Emerging Adults.
Receives: Behavioral: Multisystemic Therapy-Emerging Adults
Enhanced Treatment as UsualActive comparatorThis group will have access to an enhanced version of services typically delivered to young adults who have a substance use disorder and have been in trouble with the law.
Receives: Behavioral: Enhanced Treatment as Usual

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in number and severity of criminal charges in official records in the 16 months pre-Baseline compared with the 16 months post-Baseline.

    Changes from the 16 months pre-Baseline in offending as measured by the number and severity of criminal charges in official records compared to 16 months post-Baseline.

    Measured: 16 months pre-Baseline compared with 16 months post-Baseline.

  2. Changes from Baseline scores compared to 16 months post-Baseline Offending Behaviors (measured at 0, 2, 4, 6, 8, 12 and 16 months).

    Offending behaviors as measured using the Self-Report Offending Scale (self-reports).

    Measured: Baseline to 16 months.

Secondary outcomes (12)
  1. Changes from Baseline scores compared to 16 months post-Baseline Self-efficacy (measured at 0, 2, 4, 6, 8, 12 and 16 months).

    Self-efficacy as measured using the Self-Efficacy Scale (self-reports).

    Measured: Baseline to 16 months.

  2. Changes from Baseline scores compared to 16 months post-Baseline Goal Directedness (measured at 0, 2, 4, 6, 8, 12 and 16 months).

    Goal directedness measured using the Wills Self Control Measure (self-reports).

    Measured: Baseline to 16 months.

  3. Changes from Baseline scores compared to 16 months post-Baseline Responsibility Taking (measured at 0, 2, 4, 6, 8, 12 and 16 months).

    Responsibility taking measured using the Behavioral Indicators of Conscientiousness (self-reports).

    Measured: Baseline to 16 months.

  4. Changes from Baseline scores compared to 16 months post-Baseline Urine Drug/Alcohol Screens (measured at 0, 2, 4, 6, 8, 12 and 16 months).

    The number of positive urine screens for tetrahydrocannabinol (THC), synthetic THC, amphetamines, methamphetamines, phencyclidine (PCP), opiates, benzodiazepines, cocaine, and specific metabolites of alcohol (Ethyl glucuronide, Ethyl sulfate).

    Measured: Baseline to 16 months.

  5. Changes from Baseline scores compared to 16 months post-Baseline Treatment Usage (measured at 0, 2, 4, 6, 8, 12 and 16 months).

    The number of hospitalizations, emergency room visits and other treatments for alcohol or drug use as measured using the Time Line Follow Back (self-report) and from archival records.

    Measured: Baseline to 16 months.

  6. Changes from Baseline scores compared to 16 months post-Baseline Substance Use and Problems (measured at 0, 2, 4, 6, 8, 12 and 16 months).

    Frequency of substance use and substance-related problems as measured by the Global Appraisal of Individual Needs (self-reports).

    Measured: Baseline to 16 months.

  7. Changes from Baseline scores compared to 16 months post-Baseline Antisocial Peers Involvement (measured at 0, 2, 4, 6, 8, 12 and 16 months).

    Antisocial peer involvement measured using the Peer Delinquency Scale (self-reports).

    Measured: Baseline to 16 months.

  8. Changes from Baseline scores compared to 16 months post-Baseline Interpersonal Competence (measured at 0, 2, 4, 6, 8, 12 and 16 months).

    Social conflict and social functioning as measured using the Interpersonal Competence Scale (self-reports).

    Measured: Baseline to 16 months.

  9. Changes from Baseline scores compared to 16 months post-Baseline Housing Stability (measured at 0, 2, 4, 6, 8, 12 and 16 months).

    Housing stability as measured using the Time Line Follow Back (self-reports) and from archival records.

    Measured: Baseline to 16 months.

  10. Changes from Baseline scores compared to 16 months post-Baseline Relationship Closeness and Discord (measured at 0, 2, 4, 6, 8, 12 and 16 months).

    Relational closeness and relational discord as measured by the Network of Relationship Inventory (self-reports).

    Measured: Baseline to 16 months.

  11. Changes from Baseline scores compared to 16 months post-Baseline School/Employment Involvement (measured at 0, 2, 4, 6, 8, 12 and 16 months).

    Days in school or work (gainful activities) as measured using the Time Line Follow Back (self-reports) and from archival records.

    Measured: Baseline to 16 months.

  12. Changes from Baseline scores compared to 16 months post-Baseline Mental Health Symptoms (measured at 0, 2, 4, 6, 8, 12 and 16 months).

    The severity and number of mental health symptoms as measured using the Brief Symptom Inventory and the Posttraumatic Stress Disorder Checklist (self-reports).

    Measured: Baseline to 16 months.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted30 Jan 2017 (estimated)
  2. Study start28 Aug 2017
  3. Primary completion23 Mar 2023
  4. Study completion13 Apr 2023

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
183 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03035877
Sponsor's protocol ID
1R01DA041425-01
Status last verified
Apr 2026
First submitted
26 Jan 2017
Last updated
8 Apr 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Multisystemic Therapy-Emerging Adults and Enhanced Treatment as Usual in people with Antisocial Behavior, run by Chestnut Health Systems at 4 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 8 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 4 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in number and severity of criminal charges in official records in the 16 months pre-Baseline compared with the 16 months post-Baseline. (time frame: 16 months pre-Baseline compared with 16 months post-Baseline.). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Apr 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in